Physician profile
Jan Kemnade
NPI 1467898916
$1,515.52
in general payments reported to CMS, 2019-2025
27 companies · $569 in 2025
The $569 reported for 2025 was more than what 91% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2023: $150 · 2024: $534 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,236 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.00 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $330.67 | 2019-2025 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $225.91 | 2019-2025 | Opdivo |
| Pfizer INC. | $223.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $113.20 | 2019-2025 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $91.07 | 2024-2025 | |
| Daiichi Sankyo INC. | $87.33 | 2025 | Datroway, Enhertu, Injectafer |
| Janssen Biotech, INC. | $85.25 | 2024-2025 | Rybrevant |
| Regeneron Healthcare Solutions, INC. | $41.50 | 2024 | Libtayo |
| Glaxosmithkline, LLC. | $41.04 | 2025 | Ojjaara |
| Deciphera Pharmaceuticals INC. | $39.26 | 2025 | Romvimza, Qinlock |
| Rigel Pharmaceuticals, INC. | $31.75 | 2019 | |
| Genzyme Corporation | $24.42 | 2024 | |
| Beone Medicines USA, INC. | $23.09 | 2025 | Brukinsa |
| Array Biopharma INC | $22.58 | 2025 | Braftovi, Tukysa, Mektovi |
| Incyte Corporation | $22.05 | 2024 | Monjuvi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22.04 | 2025 | |
| Coherus Oncology, INC. | $21.91 | 2024 | |
| Stemline Therapeutics INC. | $19.86 | 2023 | Orserdu |
| Apellis Pharmaceuticals, INC. | $16.74 | 2024 | Empaveli |
| Beigene USA, INC. | $16.20 | 2024 | Brukinsa |
| Lilly USA, LLC | $16.17 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Kemnade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.